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Abstract
Background:  Phosphorothioated oligonucleotides (PS-ONs) have a sequence-independent,
broad spectrum antiviral activity as amphipathic polymers (APs) and exhibit potent in vitro antiviral
activity against a broad spectrum of herpesviruses: HSV-1, HSV-2, HCMV, VZV, EBV, and HHV-6A/
B, and in vivo activity in a murine microbiocide model of genital HSV-2 infection. The activity of
these agents against animal cytomegalovirus (CMV) infections in vitro and in vivo was therefore
investigated.
Results: In vitro, a 40 mer degenerate AP (REP 9) inhibited both murine CMV (MCMV) and guinea
pig CMV (GPCMV) with an IC50 of 0.045 μM and 0.16 μM, respectively, and a 40 mer poly C AP
(REP 9C) inhibited MCMV with an IC50 of 0.05 μM. Addition of REP 9 to plaque assays during the
first two hours of infection inhibited 78% of plaque formation whereas addition of REP 9 after 10
hours of infection did not significantly reduce the number of plaques, indicating that REP 9 antiviral
activity against MCMV occurs at early times after infection. In a murine model of CMV infection,
systemic treatment for 5 days significantly reduced virus replication in the spleens and livers of
infected mice compared to saline-treated control mice. REP 9 and REP 9C were administered
intraperitoneally for 5 consecutive days at 10 mg/kg, starting 2 days prior to MCMV infection.
Splenomegaly was observed in infected mice treated with REP 9 but not in control mice or in REP
9 treated, uninfected mice, consistent with mild CpG-like activity. When REP 9C (which lacks CpG
motifs) was compared to REP 9, it exhibited comparable antiviral activity as REP 9 but was not
associated with splenomegaly. This suggests that the direct antiviral activity of APs is the
predominant therapeutic mechanism in vivo. Moreover, REP 9C, which is acid stable, was effective
when administered orally in combination with known permeation enhancers.
Conclusion: These studies indicate that APs exhibit potent, well tolerated antiviral activity against
CMV infection in vivo and represent a new class of broad spectrum anti-herpetic agents.
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Background
Cytomegalovirus (CMV) is a ubiquitous β-herpesvirus
that asymptomatically infects immunocompetent indi-
viduals but leads to serious illness and mortality in immu-
nocompromised individuals [1,2]. Currently licensed
drugs for the treatment of CMV infection in the United
States include Foscarnet, Cidofovir, Ganciclovir and
Fomivirisen. These compounds are effective in controlling
CMV infection, but emergence of resistance and poten-
tially serious side effects limit their use [2-4]. As such, the
need for well-tolerated and potent antiviral compounds
with activity against CMV is well recognized.
Amphipathic DNA polymers (APs) are a new class of anti-
viral compounds based on the sequence-independent
activity of phosphorothioated oligonucleotides. The anti-
viral activity of these compounds against Human Immu-
nodeficiency Virus (HIV-1), Herpes Simplex Virus (and
other herpesviridae), arenaviruses, and Hepatitis C Virus
(HCV) has been previously demonstrated [5-8]. These
compounds inhibit both the entry/fusion and attachment
of these viruses [5,6,8], and in the case of HIV-1, the
amphipathic nature of these compounds was shown to
directly mediate their interaction with the core amphip-
athic α-helices in gp41 [5]. The optimal polymer size (40
mer) for antiviral activity and the specific requirement for
phosphorothioation as an enhancer of amphipathic char-
acter are well conserved in these unrelated viruses. More-
over, the amphipathic α-helical domains HIV-1 gp41
show a high degree to structural homology to analogous
amphipathic domains in the surface glycoproteins of
many type 1 fusion viruses [9-15], suggesting that these
amphipathic interactions between APs and viral fusion
glycoproteins underlie the broad-spectrum antiviral activ-
ity of these compounds.
Although the target of AP interaction in viruses other than
HIV-1 is not yet known, the structural conservation of
amphipathic alpha helical domains in the fusion glyco-
proteins of most enveloped viruses strongly suggests that
the amphipathic domains in surface glycoproteins in her-
pesviridae are a potential target for AP interaction. Thus,
the mechanism of action of these compounds appears
unrelated to the published mechanism of action for anti-
sense compounds, such as fomvirisen, which is an anti-
sense phosphorothioate oligonucleotide that blocks
CMV-specific protein synthesis by hybridizing with
mRNA from the major immediate-early transcriptional
unit of the CMV genome [16].
APs have been shown to have broad spectrum in vitro
antiviral activity against herpesviridae including HSV types
1 and 2 (HSV-1, HSV-2), Varicella Zoster Virus (VZV),
Human Cytomegalovirus (HCMV), Epstein-Barr Virus
(EBV), and Human Herpesvirus 6 types A and B (HHV-6
A/B) [6,17], demonstrating that APs might provide advan-
tages to the currently available therapies to treat herpesvi-
rus infections. Moreover, two amphipathic polymers, REP
9 (a 40 mer degenerate phosphorothioate oligonucle-
otide) and REP 9C (a 40 mer poly C phosphorothioate
oligonucleotide) were shown to be effective topically
against HSV-2 infection in a murine model of genital her-
pes [17], suggesting the potential for antiviral activity in
vivo against CMV. Here we report that APs possess anti-
CMV activity against two animal CMV strains in vitro and
potent, well tolerated prophylactic in vivo efficacy in a
murine model of systemic CMV infection via multiple
routes of administration and at parenterally administered
doses as low as 0.5 mg/kg/day.
Methods
Oligonucleotide synthesis
All oligonucleotides for in vitro use were synthesized as
described previously [5,7]. Nucleic acid sequences of oli-
godeoxynucleotides used in this study are as follows:
REP 9 (phosphorothioate) and REP 2015 (phosphodi-
ester): N40 (random incorporation of A, G, T and C); REP
9C (phosphorothioate) and REP 2110 (phosphodiester):
C40; CPG7909: 5' TCGTCGTTTTGTCGTTTTGTCGTT 3'
(B-class CPG oligonucleotide, [18]).
Compounds used for in vivo experiments (REP 9, REP 9C)
were synthesized under contract with Girindus America
Inc. under GMP-like conditions to yield high purity
sodium salts.
Nuclease resistance testing
Oligonucleotide stocks (250 μM in 10 mM Tris, pH 7.2)
were diluted to 5 μM in the presence of 1× enzyme reac-
tion buffer. For phosphodiesterase II (Sigma), a working
solution of 2 mg/ml was prepared according to the man-
ufacturer's instructions and diluted to 1.3 mg/ml in the
reaction buffer containing oligonucleotide. For other
enzymes, 100 units (1 μl) of S1 nuclease (Fermentas), or
2 units (2 μl) of Bal 31 (New England Biolabs) or 20 units
(1 μl) of exonuclease I (New England Biolabs) were added
to the reaction buffer containing oligonucleotide. Reac-
tion conditions were as follows: phosphodiesterase - 24 h
at 37°C, S1 nuclease - 4 h at 37°C, Bal31 - 4 h at 30°C,
and exonuclease I - 4 h at 37°C. These conditions were
established to result in the complete digestion of a 40 mer
degenerate phosphodiester oligonucleotide (REP 2015 -
see table 1). Controls of all equivalent concentrations of
oligonucleotides in the various enzyme buffers were sub-
jected to the same reaction conditions in the absence of
enzyme. Following incubation, reactions were stopped by
heating at 70-90°C for 4 min before loading onto precast
15% urea-polyacrylamide gels (Biorad). Gels were run for
60 min at 100 volts and a 10 bp ladder (Invitrogen) wasVirology Journal 2009, 6:214 http://www.virologyj.com/content/6/1/214
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used as a size control. Gels were then stained with ethid-
ium bromide (Invitrogen) and oligonucleotides and the
degradation products were visualized by UV photography.
Stability was assessed relative to no enzyme controls by
estimating the proportion of full length oligonucleotide
present using a qualitative scale: - = no full length oligo-
nucleotide present, + = 0-25% full length present, ++ = 25-
75% full length present, +++ = 75% or greater full length
present and ++++ = no degradation of full length oligonu-
cleotide detected. None of these reaction conditions
induced any measurable degradation of any of the oligo-
nucleotides in the absence of enzyme (data not shown).
Cells and virus
NIH 3T3 cells (ATCC CRL1658) were grown in Dulbecco's
modified Eagle's medium (DMEM, Mediatech, Herndon,
VA) supplemented with 10% fetal bovine serum (FBS,
Hyclone, Thermo-Fisher Scientific), 7.5% Sodium Bicar-
bonate, 4 mM HEPES, 2 mM L-glutamine, and gentamicin
in a humidified 5% CO2 incubator at 37°C. Parent stocks
of murine cytomegalovirus (MCMV, strain K181+) were
kindly provided by Dr. Edward Mocarski (Emory Univer-
sity School of Medicine, Atlanta Georgia). The K181+
virus stocks were grown in NIH 3T3 cells and the resulting
tissue culture-passaged stocks were used in all of the in
vitro MCMV studies and the majority of in vivo studies.
The Smith strain of MCMV was purchased (ATCC, VR-
1399) and a salivary gland-passaged virus stock was used
in one in vivo study as described in the text. The salivary
gland virus stock was prepared from infected salivary
glands at 21 days after infection of 6 week old BALB/c
mice with the Smith strain [19]. MCMV (Smith) titers
were determined by plaque assay on murine embryonic
fibroblasts (MEF) from BALB/c mice. MCMV (K181+) tit-
ers were determined by plaque assay on NIH 3T3 cells
[20,21]. Guinea pig CMV (GPCMV, Strain 22122) was
purchased (ATCC, VR-682) and was grown in guinea pig
lung fibroblast (GPL) cells (ATCC CCL-158). GPL cells
were maintained in F-12 media (Invitrogen Corporation,
Grand Island, NY) supplemented with 10% FBS
(Hyclone, Thermo-Fisher Scientific) and penicillin/strep-
tomycin in a humidified 5% CO2 incubator at 37°C.
GPCMV titers were determined by plaque assay on GPL
fibroblast monolayers overlaid with media containing
50% Basal Medium Eagle (Sigma-Aldrich Corporation)
and 1.5% methylcellulose [22]. All virus stocks were
stored at -70°C and re-titered before use in experiments.
Virological assays
For MCMV plaque assays, dilutions of virus stocks or 10%
mouse tissue sonicates were adsorbed onto 70% conflu-
ent NIH 3T3 monolayers for one hour at 37°C, then over-
laid with 1.5% carboxymethyl cellulose (CMC): 2×
modified Eagle's medium (1:1) as previously described
[20,21]. After incubation at 5% CO2 for 6 days, the CMC
overlay was removed and the monolayers were fixed with
methanol and stained with Giemsa to determine the
number of plaques. To measure the antiviral activity of the
compounds against MCMV and GPCMV, plaque reduc-
tion assays were performed. For the plaque reduction
assay, 100 plaque-forming units (pfu) of MCMV (K181+)
or GPCMV were adsorbed onto NIH 3T3 cells or GPL cells
and known amounts of compound ranging from 0.01 μM
to 1.0 μM were included in the one hour infection of the
NIH 3T3 cells (for MCMV) and GPL cells (for GPCMV)
and also included in the overlay media of the plaque
assay. The assays were performed in duplicate wells in
three separate experiments. The IC50 for each compound
was calculated as the concentration of compound which
reduced the number of plaques by 50% compared to the
untreated control. Cytotoxicity of compounds was
assessed by Giemsa staining of uninfected murine fibrob-
lasts or Crystal Violet staining of uninfected guinea pig
fibroblasts that were incubated with increasing concentra-
tions of REP 9 compound ranging from 1.0 μM to 100 μM
and compared microscopically to control monolayers that
were not exposed to compound.
Time-of-Addition assay
To investigate the antiviral activity of REP 9 on MCMV
replication when the compound was added at different
times during infection, time-of-addition assays were per-
formed using the plaque reduction assay as described
above with the following modifications. Briefly, in each
well, 10 μM REP 9 or no compound was added with 200
pfu of MCMV (K181+) at the time of infection. After incu-
bation for 2 hours, the virus inoculum was removed and
the wells were overlaid with CMC containing 10 μM REP
Table 1: Nuclease resistance of REP 9, REP 9C and their non-phosphorothioated analogs
Nuclease resistance (- = fully degraded, ++++ = fully resistant)
compound sequence chemistry Phosphodiesterase II S1 Nuclease Bal 31 Exo I
REP 2015 N40 (degenerate) PO - - - -
REP 9 PS ++ - ++++ ++++
REP 2110 C40 PO ++++ ++ - -
REP 9C PS ++++ ++ ++++ ++++
PO = phosphodiester, PS = phosphorothioateVirology Journal 2009, 6:214 http://www.virologyj.com/content/6/1/214
Page 4 of 14
(page number not for citation purposes)
9 (thus present during entire infection time) or no com-
pound as a control. Additional wells were infected with
MCMV for 2 hours or 10 hours in the absence of REP 9,
then the virus inoculum was removed, and overlaid with
CMC containing 10 μM REP 9, (thus present only at 2
hours or 10 hours after infection). As a control, duplicate
sets of wells were set up and cells were washed twice with
media to remove excess non-absorbed virus or to remove
excess compound. Lastly, similar wells containing 10 μM
Ganciclovir (Sigma) added at 2 hours or 10 hours as a
control for inhibition of MCMV replication were used.
The wells were then incubated at 37°C and 5% CO2 for six
days and stained with Giemsa to enumerate the average
number of plaques in triplicate wells for each inhibition
assay. The time-of-addition studies were performed twice
and the % reduction of plaques was determined by com-
parison to the number of plaques in the control wells.
Mice and infection
Female BALB/c mice were purchased from Jackson Labo-
ratories (Bar Harbor, ME). Three-week old or five-week
old mice (8 mice/group) were infected with 1 × 105 pfu of
MCMV (K181+) by intraperitoneal (i.p.) inoculation and
maintained under specific pathogen-free conditions at
Cincinnati Children's Hospital Medical Center. In one
study, 5-7 week old mice were infected with 1 × 103 pfu of
MCMV (Smith) by i.p., intravenous (i.v.), or subcutane-
ous (s.c.) inoculation and housed in the animal facility at
Laval University, Quebec. At various days post infection
(dpi), mice were sacrificed, tissues were collected and
10% tissue sonicates were prepared for virus titration by
plaque assay.
In vivo antiviral activity
APs (REP 9, REP 9C), or saline control, were administered
to mice by i.p., i.v., or s.c. injection daily at the indicated
doses beginning 2 days prior to infection and continued
daily for 5 to 6 days as described in the text. For i.p. injec-
tion, APs were administered 3 hours prior to infection. On
day 0, 3 hours post treatment, the mice were inoculated
with virus, and at 3 days post infection (dpi), the mice
were sacrificed and the virus titers in the spleen and liver
were determined. The spleens were placed in pre-weighed
tubes to determine the weight of the spleens at 3 dpi. In
some studies, REP 9C was delivered by oral dosing (p.o.,
100 μl volume) starting at 2 days prior to infection or in
dose response experiments by i.p. injection to 3 week old
BALB/c mice starting at 8 days prior to infection. In oral
dosing studies, mice were fasted for 3 hours before dosing
each day and for 1 hour following dosing. Mice were
weighed daily prior to treatment to determine the dose of
compound administered to the mice. As a control in some
studies, mice were treated daily for 5 consecutive days by
i.p. injection of 25 or 50 mg/kg Ganciclovir (GCV, Sigma).
In all studies, mice were also monitored for signs of toxic-
ity by weight loss, ruffled fur, and level of activity. For oral
REP 9C formulations, the intestinal absorption enhancer
n-tetradecyl-β-D-maltopyranoside (TDM, Anatrace, Inc)
was prepared at 0.25% in normal saline. The appropriate
amount of REP 9C was dissolved in the TDM solution to
yield a 400 mg/kg dose per 100 μl solution. A second
intestinal absorption enhancer, sodium caprate (C10,
Sigma) was formulated in normal saline to yield 100 mg
in each oral dose in combination with 400 mg/kg of REP
9C. These solutions were filter sterilized and stored at 4°C
and then allowed to come to room temperature prior to
administration.
AP stimulation of cytokine production in human PBMC 
cells
Human peripheral blood mononuclear cells (PBMCs)
were isolated from Leukopaks obtained from Biological
Specialty Corporation (Colmar, PA) by centrifugation on
a Ficoll-Hypaque density gradient. The cells were washed
and resuspended in AIM V (InVitrogen; Carlsbad, CA)
serum-free medium (containing 50 μg/ml streptomycin
sulfate and 10 μg/ml gentamicin sulfate) at a concentra-
tion of 4 × 106 cells/ml. For cytokine stimulation, the cells
were diluted in an equal volume of AIM V medium (con-
taining 2× final drug concentration) to yield a final con-
centration of 2 × 106 cells/ml. PBMCs were stimulated in
a 48-well format (0.5 ml cells + 0.5 ml drug) for 48 hr with
32 nM of each compound. At study endpoint, cell super-
natants were tested in each of the assay platforms to deter-
mine the specific cytokines which were stimulated. The
following cytokines were measured using kits from Meso
Scale Discovery (MSD, Inc., Gaithersburg, MD): Human
IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8 IL-10, IL-12p70, IL-
13, TNF-α and IFN Inducible Protein 10 (IP-10). These
cytokine levels were determined in culture supernatant by
using a multiplex platform developed by MSD. Custom-
coated MULTI-SPOT plates (7-, 4-, or 1-Spot 96-well for-
mat) were used in which the cytokines could be simulta-
neously detected within each well of the plate. For each,
10  μl of a calibrator (containing all human cytokine
standards) or supernatant was added to appropriate wells
of the plate and incubated at room temperature for 1-2
hours with vigorous (300-1000 rpm) shaking. This was
followed by three washes with PBS-0.05% Tween-20,
addition of 20 μl/well of a 1 μg/ml detection antibody
solution (containing antibodies to the cytokines in each
kit type), and incubation of the plate at room temperature
for 1-2 hours with vigorous shaking. After three washes
(PBS-0.05% Tween), 150 μl/well of 2× MSD Read Buffer
T was added and the plate was analyzed on a Sector 6000
instrument. Cytokine concentrations in each sample were
calculated from calibration curves based on four-parame-
ter logistic algorithms and expressed as pg/ml. In addi-
tion, a human IFN-α kit from BioSource (Camarillo, CA)
kit was used for this study. The high sensitivity protocol
(0-500 pg/ml) was used to determine IFN-α levels in cul-
ture supernatants. A volume of 100 μl of calibrator orVirology Journal 2009, 6:214 http://www.virologyj.com/content/6/1/214
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supernatant was added to appropriate wells of the plate
and incubated at room temperature for 1-2 hours. The
wells were then washed once in the kit wash buffer, fol-
lowed by addition of 100 μl of antibody, and incubation
of the plate at room temperature for 1-2 hours. After three
washes in kit wash buffer, 100 μl of horseradish peroxi-
dase reagent was added, and the plate was incubated at
room temperature for 1 hour. After four washes in kit
wash buffer, 100 μl of TMB substrate was added, and the
plate was incubated for 15 minutes at room temperature.
To stop the reaction, 100 μl acid stop solution was added,
and the well absorbance were determined at 450 nm.
Cytokine concentrations in each sample were calculated
from calibration curves based on four-parameter logistic
algorithms and expressed as pg/mL.
Statistical analysis
All virus titer data shown are expressed as mean virus titer
(log10 pfu/ml) +/- standard error. Statistical analysis was
performed using the Student's t test (GraphPad Instat Pro-
gram). P values of < 0.05 (two-tailed) were considered to
indicate a significant difference.
Results
APs exhibit in vitro antiviral activity against animal 
cytomegaloviruses
The strict species specificity of HCMV infection limits the
study of HCMV in animal models. To further explore the
in vivo antiviral activity of APs against CMV infection, it
was first necessary to determine whether REP 9 (a 40 mer
degenerate AP) showed antiviral activity in plaque reduc-
tion assays against CMV for which small animal models
exist. In our assays, REP 9 showed potent activity against
both MCMV and GPCMV, with IC50s of 0.045 ± 0.004
μM and 0.16 ± 0.07 μM, respectively, that were compara-
ble to the previously established IC50 of REP 9 against
HCMV [17]. In addition to reducing the numbers of
plaques observed with increasing concentrations of REP 9,
the plaque size also appear to be reduced. A second com-
pound, REP 9C, also showed similar activity against
MCMV, with an IC50 of 0.048 ± 0.005 μM. Neither com-
pound demonstrated significant toxicity on fibroblasts,
with CC50s > 100 μM. A similar lack of toxicity was
reported for REP 9 toxicity on human foreskin fibroblasts
(HFFs) [17].
Previously, it was shown that REP 9 inhibits HSV-2 infec-
tion at multiple steps, including binding, entry, and post-
entry stages of the virus replication cycle [6]. To determine
whether REP 9 acts to inhibit MCMV in a similar fashion,
we performed modified time-of-addition assays using
MCMV infection of NIH 3T3 cells. Briefly, triplicate wells
of cells were infected with MCMV in the absence or pres-
ence of 10 μM REP 9 at the beginning of the assay or with
addition of REP 9 at 2 hours or 10 hours after infection.
As shown in Figure 1, the number of plaques per well were
dramatically reduced by 99% compared to control wells
when REP 9 was present during the virus inoculation and
during the 6 day plaque assay. When the drug was present
only during the first two hours of infection, followed by
no drug present in the overlay, a 78% reduction in the
total number of plaques was observed, indicating that
REP 9 inhibits viral infection as early as during the two
hours of infection. To further determine whether REP 9
shows activity following post-entry, compound was
added after 2 hours post infection or after 10 hours post
infection. As shown in Figure 1, addition of REP 9 in the
overlay at 2 hours after infection and for the duration of
the assay resulted in a 63.5% reduction in the number of
plaques observed, whereas the addition of REP 9 in the
overlay at 10 hours after infection did not significantly
reduce the number of plaques, yielding approximately
83% of the total number of plaques compared to the con-
trol wells. Addition of REP 9 at the time of infection or
even after 2 hours after infection resulted in markedly
smaller plaques detected in the assay, whereas when REP
9 was added at 10 hours after infection, the size of the
plaques were only slightly smaller than the size of plaques
in the untreated wells. In one study, addition of 10 μM
Ganciclovir (GCV) at 2 hours after infection and for the
duration of the assay resulted in ~70% reduction in the
number of plaques observed (data not shown), as might
be expected since the reported IC50 of GCV against
MCMV is ~5 μM [23]. As an additional control, wash steps
In vitro REP 9 Activity against MCMV infection at Different  Times during Infection Figure 1
In vitro REP 9 Activity against MCMV infection at 
Different Times during Infection. Plaque reduction 
assays were performed with no REP 9 compound added or 
10 μM REP 9 present throughout the assay, or present for 0-
2 hours of the assay, or present only after 2 hours or 10 
hours after infection and the remainder of the assay. Addi-
tion of 10 μM Ganciclovir in the assay served as a control for 
inhibition of MCMV replication. Mean antiviral activity is 
depicted as percentage of plaques in REP 9 wells relative to 
the percentage of plaques in control wells. Data is from two 
separate studies and assays performed in triplicate wells.
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following removal of the virus inoculum and/or drug did
not significantly affect the number of plaques observed in
the assays (data not shown).
In vivo effect of REP 9 against murine cytomegalovirus
Infection of mice with MCMV mimics the infection of
humans with HCMV and serves as a well characterized
small animal model to assess whether antivirals are active
during in vivo MCMV infection. Following i.p. infection,
replicating MCMV is found in a number of tissues, includ-
ing the spleen, liver, lung, and salivary glands [24-28].
Using this model, mice were treated by i.p. injection with
REP 9 either once daily (10 mg/kg total) or twice daily (20
mg/kg total) beginning at 2 days prior to i.p. infection
with 1 × 105 pfu of MCMV (K181+). Treatment was con-
tinued for 3 days after infection (dpi), at which time the
mice were sacrificed and the virus titers in the spleens and
livers were determined by plaque assay. As shown in fig-
ure 2, REP 9 had a pronounced antiviral effect, signifi-
cantly reducing MCMV replication in the spleen (figure
2a) regardless of whether the mice were treated with 10
mg/kg REP 9 (p = 0.011) or 20 mg/kg REP 9 (p = 0.0006)
as compared to the saline-treated control mice. REP 9
treatment also significantly reduced MCMV replication in
the livers (figure 2b) of these mice at both the 10 mg/kg
REP 9 (p = 0.009) and 20 mg/kg REP 9 doses (p = 0.004).
Moreover, in this experiment, while 8/8 of the spleens and
7/8 of the livers of the saline-treated control mice had
detectable virus, fewer mice treated with REP 9 had detect-
able MCMV in the spleen (5/8 mice at 10 mg/kg and 20
mg/kg) and the liver (3/8 mice at 10 mg/kg and 2/8 mice
at 20 mg/kg). Taken together, this data suggests that the
antiviral activity of REP 9 may be more potent in the liver
than in the spleen. Unexpectedly, REP 9 treatment
resulted in splenomegaly as shown by the significant
increased spleen weights of the treated mice compared to
control mice (figure 2c). Lastly, extending the REP 9 treat-
ment for an additional 2 days to 5 dpi did not significantly
reduce the virus levels in the spleens and livers compared
to saline-treated control mice (data not shown).
Because it is possible that the efficacy of REP 9 therapy was
enhanced because treatment and viral infection were both
i.p., we next altered both the route of treatment and the
route of infection. In this experiment, mice were treated
i.v. with 1 or 10 mg REP 9/kg/day or treated i.p. or s.c.
with 20 mg REP 9/kg/day, followed by i.v. inoculation
with 1 × 103 pfu MCMV (Smith). Treatment began 2 days
prior to i.v. inoculation with MCMV and continued for 3
days after infection. In this study, treatment with REP 9 by
either the s.c. or i.p. routes (20 mg/kg/day) or i.v. route
(10 mg/kg/day) reduced MCMV replication in the spleen
comparable to i.v. treatment with 25 mg/kg/day GCV,
indicating that the antiviral activity of REP 9 was inde-
pendent of the route of REP 9 administration (figure 3a).
REP 9 inhibition of virus replication was also not depend-
ent on the MCMV strain or the route of infection.
Splenomegaly was also observed at 3 dpi following all
three routes of REP 9 administration at 10 mg/kg or 20
mg/kg but was not observed following i.v. administration
of 1 mg/kg REP 9 (figure 3b). Mice which were treated i.v.
with 25 mg/kg GCV or control mice infected by the i.v.
route, did not exhibit splenomegaly. A dose effect was
observed following i.v. treatment with 1 mg/kg REP 9
which was not effective at inhibiting virus titers or induc-
ing splenomegaly. In this study, REP 9 (10 mg/kg/day)
administered by the i.v. route had a small but significant
antiviral effect. However, these mice showed significant
signs of distress (inactivity, ruffled fur and weight loss).
Immunostimulatory activity vs. antiviral activity of APs
While REP 9 was active against MCMV infection in all of
the initial experiments, REP 9 administration resulted in
significant splenomegaly in the treated mice (figures 2c
and 3b) compared to saline-treated mice. Due to its
degenerate nature, REP 9 contains a small percentage of
CpG motifs. The mild CpG-like activity of the REP 9 com-
pound could contribute to the splenomegaly seen in these
experiments and also provide antiviral activity. To investi-
gate this issue, we designed an analog of REP 9 which had
no CpG motifs, REP 9C (C40). To determine whether REP
9C had reduced immunostimulatory activity compared to
the REP 9 compound, the ability of REP 9 and REP 9C to
stimulate cytokine production in human PBMCs was
assessed and compared to a well defined B-class CpG
oligo (CPG 7909, [18]) as a control (figure 4). In this
experiment, the control compound, CPG7909 at 32 nM
exhibited the classical TLR-9 mediated induction of
cytokine secretion in human PBMCs, with significant
inductions of IFN-γ, IFN-α, IL-1β IL-6, IL-10, IP-10 and
TNF-α. At the same concentration, REP 9 stimulated the
secretion of these same cytokines as CPG 7909 except IFN-
γ but on a much reduced scale, consistent with the pres-
ence of mild CpG like activity and observations of
splenomegaly in vivo. However, REP 9C exposure to
PBMCs resulted in a weaker induction of cytokines in gen-
eral compared to REP 9. For many cytokines induced by
CPG 7909 or REP 9, there was no induction of cytokines
in PBMCs by REP 9C. Thus, REP 9C shows minimal or no
activity in inducing cytokine secretion in comparison to
REP 9 or the positive control CPG 7909.
In vivo effect of REP 9C against murine cytomegalovirus
REP 9C was then tested in vivo to determine if the lack of
CpG motifs and reduced cytokine inducing activity of this
analog would still retain the antiviral activity of REP 9
without inducing splenomegaly. Since our previous expe-
rience with these compounds indicated that i.p. adminis-
tration with 10 mg/kg/day was well tolerated, mice were
treated once daily with 10 mg/kg of REP 9 or REP 9CVirology Journal 2009, 6:214 http://www.virologyj.com/content/6/1/214
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In vivo Activity of REP 9 against MCMV Replication in the Spleen and Liver Figure 2
In vivo Activity of REP 9 against MCMV Replication in the Spleen and Liver. Virus titer levels of MCMV in spleen (a) 
and liver (b) and spleen weights (c) of mice treated with 10 mg/kg REP 9 once daily (QD - gray bars) or twice daily (BID - white 
bars). Five-week old mice (8 mice/group) were treated by daily i.p. administration of saline or REP 9 starting 2 days prior to i.p. 
inoculation with 1 × 105 pfu of MCMV (K181+) and continued to 3 days post infection. Data represents results from one typi-
cal experiment; Mean +/- standard deviation (n = 8). When observed, animals in each treatment group with no detectable 
MCMV titer are indicated as x negative/8 total below each bar. The limit of detection for the plaque assay is 10 pfu/ml of tissue 
homogenate. Virus titers depicted below the limit of detection indicate where samples were negative at the limit of detection 
but positive for virus in undiluted samples. P values are shown in figure.
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beginning at 2 days prior to infection and continuing
until 3 dpi. In this study, both REP 9 and REP 9C showed
potent antiviral activity in the liver (figure 5b) while REP
9C appeared more efficacious in the spleen (figure 5a).
Further, REP 9C did not induce detectable splenomegaly
compared to the saline treated control group (figure 5c)
while REP 9 treated animals again showed signs of
splenomegaly. However, administration of REP 9 to unin-
fected mice did not induce splenomegaly, suggesting that
virus infection contributes to the REP 9-induced splenom-
egaly observed in our studies.
To further evaluate the antiviral activity of REP 9C in vivo,
a second experiment was performed to compare the in
vivo antiviral activity of REP 9C with GCV (figure 6). In
this experiment, the majority of animals treated with
either 10 mg/kg or 20 mg/kg REP 9C as described above
had undetectable levels of MCMV in both the spleen (7/8
animals negative at both doses, figure 5a) and liver (8/8
and 6/8 animals negative, respectively, figure 5b). In com-
parison, 6-7 of the 8 untreated animals had detectable
virus in the spleens or livers while none of the animals
treated with 50 mg/kg GCV had detectable virus in either
organ. Notably, no signs of distress was observed in ani-
mals treated with REP 9C at 10 or 20 mg/kg/day, similar
to REP 9.
Nuclease stability of REP 9 and REP 9C
Both REP 9 and REP 9C exhibited comparable antiviral
activity in the liver and, to a lesser degree, in the spleen.
Since all phosphorothioate oligonucleotides in general
are known to accumulate preferentially in the liver and to
a lesser extent in the spleen [29-34], the differential activ-
ity of these two compounds in the spleen was most likely
not due to differences in pharmacokinetic behavior but
rather to differences in compound stability. Since nucle-
ase activity is the major degradative pathway of these com-
pounds in vivo, the nuclease stability of both REP 9 and
REP 9C were examined (table 1). Both REP 9 and REP 9C
and their non-phosphorothioated counterparts were
exposed to a variety of nucleases under optimal degrada-
tion conditions (see methods) and then subjected to qual-
itative analysis by denaturing gel electrophoresis. Under
our testing conditions, the control, non-phosphorothio-
ated (phosphodiester) degenerate oligonucleotide (REP
2015) had no detectable stability to any of the nucleases
tested as expected. REP 9 was fully resistant to Bal31 and
Exo 1 digestion but had only moderate stability to Phos-
phodiesterase II and was not stable to S1 nuclease activity.
The poly C phosphodiester oligonucelotide was com-
pletely stable to phosphodiesterase digestion but was only
moderately stable to S1 nuclease digestion and displayed
no resistance to Bal 31 and Exo 1 activity. REP 9C, how-
ever, was completely resistant to all enzymes except for S1
nuclease to which it still displayed a high degree of resist-
ance. Thus, REP 9C has a superior nuclease resistance pro-
file to REP 9 and this may account for the better antiviral
activity with this analog.
Antiviral dose response of REP 9C
To determine the effect of dose on REP 9C antiviral activ-
ity, a dose range study of REP 9C was performed. Initial
dose response experiments (figure 3a) indicated that 1
mg/kg/day of REP 9 was ineffective in this model when
administered i.v. for 5 days. In this study, the dose of REP
9C ranged from 0.5 mg/kg, twice daily, to 10 mg/kg, once
daily, administered i.p. to mice starting at 8 days prior to
infection and treated for 11 consecutive days. As shown in
Figure 7a, REP 9C administered at 10 mg/kg once daily for
11 consecutive days significantly decreased virus replica-
Antiviral Effects of REP 9 in the Spleen Following Different  Routes of Administration Figure 3
Antiviral Effects of REP 9 in the Spleen Following Dif-
ferent Routes of Administration. Viral titers in the 
spleen (a) and spleen weights (b) of mice treated with either 
GCV or REP 9 are shown. Five week old mice (8 mice/group) 
were treated daily with saline or REP 9 starting 2 days prior 
to i.v. inoculation with 1 × 103 pfu of MCMV (Smith) and con-
tinued until 3 days post infection. REP 9 was administered by 
i.v, i.p. or s.c. route of injection at 1 mg/kg, 10 mg/kg, or 20 
mg/kg. As a control, 25 mg/kg GCV was administered by i.v. 
route of injection. Data represents results from one experi-
ment; mean +/- standard deviation (n = 8). P values are 
shown in figure.
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tion in the liver at 3 dpi compared to the saline treated
control group (p = 0.005, 4/8 mice MCMV negative). REP
9C also significantly inhibited virus replication in the liver
when administered twice daily (BID) at treatment doses
of 5 mg/kg (p = 0.003, 3/8 mice MCMV negative), 3 mg/
kg (p = 0.002, 5/8 MCMV negative), 2 mg/kg (p = 0.02, 3/
8 mice MCMV negative), and 0.5 mg/kg (p = 0.05, 8/8
mice with detectable virus in the liver). Thus, all doses
except 0.5 mg/kg BID reduced the numbers of animals
with detectable MCMV in their livers. Similar results were
seen in a second study (data not shown). It is possible that
the known liver accumulation and long half-life of phos-
phorothioate oligonucleotides in rodent species [29,30]
may have lead to increased accumulation of drug, which
could explain the increased efficacy seen in this experi-
ment at lower REP 9C doses compared to those using
shorter treatments.
Antiviral activity of REP 9C following oral dosing
The REP 9C compound has been shown to be highly acid
resistant [17], making it well suited for oral administra-
tion in the absence of a controlled release formulation. To
determine whether REP 9C exhibited antiviral efficacy fol-
lowing oral dosing, an oral formulation of 400 mg/kg of
REP 9C in 0.25% (w/v) TDM (tetradecyl-β-D-maltopyra-
noside) or combined with 100 mg of sodium caprate
(C10) was used. TDM belongs to a family of alkylated sac-
charides known to enhance the intestinal absorption of
high molecular weight compounds with poor oral bioa-
vailability [35,36] and sodium caprate has previously
been shown to substantially enhance to the oral bioavail-
ability of phosphorothioate oligonucleotides in human
patients [37,38]. A total volume of 100 μl of either REP 9C
+ TDM or REP 9C + C10 was delivered orally by gavage
with feeding tubes once daily for 5 consecutive days start-
ing at 2 days prior to infection. Control mice were treated
with 100 mg C10 in normal saline. Mice were infected i.p.
with 1 × 105 pfu MCMV at day 0 and the livers were col-
lected and titered at 3 dpi. As shown in figure 7b, REP 9C
delivered orally with 0.25% TDM or 100 mg C10 signifi-
cantly reduced the MCMV viral loads in the livers. The
reduction in viral titers and number of mice with undetec-
table MCMV in mice treated with REP 9C + TDM or REP
9C + C10 were comparable to the control group which
received 20 mg/kg REP 9C via i.p. injection. Oral admin-
istration of REP 9C at 400 mg/kg was shown to have no
antiviral activity when administered without an intestinal
absorption enhancer (data not shown). Mice treated
orally with C10 alone or with C10 in combination with
REP 9C developed weight loss, inactivity and ruffled fur
but none of these complications were observed in mice
which received the TDM + REP 9C oral formulation. The
animal deaths which occurred in this study (one mouse in
the C10 alone group, one mouse in the REP 9C + C10
In vitro Stimulation of cytokine release in human PBMCs by REP 9 and REP 9C Figure 4
In vitro Stimulation of cytokine release in human PBMCs by REP 9 and REP 9C. Human PBMCs were exposed to 
no compound, CPG 7909, REP 9, and REP 9C, and levels of secreted cytokines after 48 h of induction were determined as 
described in the material and methods. Data is depicted on different scales (7, 70, 300, and 20,000 pg/ml) to demonstrate dif-
ferences in cytokine levels measured. Values plotted are mean +/- standard deviation (n = 3). * = statistically insignificant differ-
ence in cytokine concentrations compared to untreated controls, + = statistically significant reduction in cytokine 
concentrations (REP 9C versus REP 9) (p < 0.05).
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Comparison of In vivo Antiviral Activity of REP 9 and REP 9C Figure 5
Comparison of In vivo Antiviral Activity of REP 9 and REP 9C. Virus titer levels in the spleens (a) and livers (b) and 
spleen weights (c) are shown for mice treated with 10 mg/kg REP 9 or REP 9C. Five-week old mice (8 mice/group) were 
treated by daily i.p. administration of saline, REP 9, or REP 9C starting 2 days prior to i.p. inoculation with 1 × 105 pfu of MCMV 
(K181+) and continued to 3 days post infection. Data represents results from three separate experiments; Mean +/- standard 
error (n = 8/experiment). When observed, animals in each treatment group with no detectable MCMV titer are indicated as x 
negative/8 total below each bar. P values are shown in figure.
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group, and two mice in the REP 9C + TDM group) were
attributed to mechanical trauma from the oral administra-
tion procedure and were not considered to be drug
related.
Discussion
The studies of REP 9 and REP 9C presented here demon-
strates for the first time the in vivo activity of APs against
systemic MCMV infection in two important tissues, the
spleen and liver, where CMV replicates and establishes
long term persistent infection. APs have been shown to
have antiviral activity in vitro against HSV-1, HSV-2,
HCMV, VZV, EBV and HHV-6A/B [6,17], and REP 9 and
REP 9C have been previously shown to prevent the topical
transmission of HSV-2 [17]. Thus, the in vivo prophylactic
activity of REP 9 and REP 9C against MCMV infection in
In vivo Antiviral Comparison of REP 9C and Ganciclovir Figure 6
In vivo Antiviral Comparison of REP 9C and Ganci-
clovir. Virus titer levels in the spleens (a) and livers (b) from 
mice treated with 10 or 20 mg/kg REP 9C or 50 mg/kg Gan-
ciclovir (GCV). Five week old mice (8 mice/group) were 
treated by daily i.p. administration of saline, REP 9C or GCV 
starting at 2 days prior to i.p. inoculation with 1 × 105 pfu of 
MCMV (K181+) and continued for 3 days. Data represents 
results from one experiment; mean +/- standard deviation (n 
= 8). When observed, animals in each treatment group with 
no detectable CMV titer are indicated as x negative/8 total 
below each bar. P values are shown in figure.
A
B
control 10 mg/kg
REP 9C
20 mg/kg
REP 9C
(7/8 negative)
50 mg/kg
GCV
(7/8 negative) (2/8 negative) (8/8 negative)
control 10 mg/kg
REP 9C
20 mg/kg
REP 9C
(6/8 negative)
50 mg/kg
GCV
(8/8 negative) (1/8 negative) (8/8 negative)
Spleen
Liver
0
1
2
3
4
5
V
i
r
u
s
 
t
i
t
e
r
 
(
l
o
g
 
P
F
U
/
m
l
)
p=0.005
p=0.010
p=0.003
0
1
2
3
4
V
i
r
u
s
 
t
i
t
e
r
 
(
l
o
g
 
P
F
U
/
m
l
)
p=.0130
p=.0003 p=.0003
In vivo Antiviral Dose Effect of REP 9C following Intraperito- neal or Oral Dosing Figure 7
In vivo Antiviral Dose Effect of REP 9C following 
Intraperitoneal or Oral Dosing. (a) Virus titer levels in 
the livers from mice treated with various doses of REP 9C. 
Three-week old mice (8 mice/group) were treated by daily 
i.p. administration of saline or 10 mg/kg (QD), 5 mg/kg (BID), 
3 mg/kg (BID), 2 mg/kg (BID), or 0.5 mg/kg (BID) of REP 9C 
starting at 8 days prior to infection with MCMV and contin-
ued for 11 days. Data represents results from one of two 
separate experiments; Mean +/- standard deviation (n = 8). 
(b) Virus titer levels in the livers from mice treated orally 
with 100 mg sodium caprate (C10), 20 mg/kg REP 9C, 400 
mg/kg REP 9C in 100 mg C10, and 400 mg/kg REP 9C in 
0.25% (w/v) TDM. Five-week old mice (8 mice/group) were 
treated by daily oral administration of C10 or REP 9C + C10 
or TDM starting 2 days prior to i.p. inoculation with 1 × 105 
pfu of MCMV (K181+) and continued to 3 days post infec-
tion. Data represents results from one of two separate 
experiments with similar outcomes; mean +/- standard error 
(n = 8). The asterisk indicates groups in which mice died due 
to non-drug related technical difficulties with oral administra-
tion. In (a) and (b), mice with no detectable MCMV titer are 
indicated as x negative/8 total below each bar. P values are 
shown in figure.
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mice suggests that APs may have the potential to be broad
spectrum anti-herpetic prophylactic agents in vivo. These
initial murine studies presented here are considered an
initial proof of concept of the ability of REP 9 and REP 9C
to target CMV infection in the liver and spleen.
Traditionally, the activity of phosphorothioate oligonu-
cleotides in rodent models has been difficult to achieve at
doses lower than 10 mg/kg/day due to the weaker organ
accumulation and much shorter half-life of these com-
pounds compared to primate species [33,34]. Phospho-
rothioate oligonucleotides accumulate primarily in the
liver, kidney, spleen and lung of mammalian species [29-
34] and as phosphorothioate oligonucleotides, APs share
these same general characteristics (data not shown) and
are thus ideally suited to treat viral infections in these
organs. Moreover, at equivalent mg/kg dose, phospho-
rothioate oligonucleotide accumulation in these target
organs is known to be substantially increased in primates
compared to rodent species while the half life in these tar-
get organs increases from 5 days in rodents to 28 days in
primates [33,34]. In fact, efficacious dose levels of phos-
phorothioate oligonucleotides of 10 mg/kg/day in rodent
species have translated into effective dosing at 200 mg
once weekly in humans [39,40]. This suggests that effec-
tive antiviral activity with APs could be achievable with a
reasonable dosing regimen in patients.
APs in general have been shown to be entry/attachment
inhibitors in HIV-1, HSV-1/2, arenaviruses, and more
recently, HCV [5-8]. The inhibition of viral entry/attach-
ment by APs appears to be well conserved in enveloped
viruses from divergent families. Similarly, the results from
figure 1 indicates that the majority of the REP 9 activity
against MCMV appears to occur at early times after infec-
tion and thus most likely affects binding and entry as
shown for HSV-2 [6]. Some REP 9 activity is also observed
when drug is added as late as 10 hours after infection.
Thus it seems reasonable to assume that mechanism (s)
similar to that reported for REP 9 against HSV-2 are
responsible at least in part for the antiviral activity of APs
against MCMV infection.
APs have been shown to directly interact with amphip-
athic alpha helical core fusion domains in HIV-1 [5]
which are structurally analogous to the amphipathic
alpha-helical structures which are present in gB of HSV
[11] and the gH of all herpesviruses [41]. Moreover, these
amphipathic domains in gH can be complemented by the
core amphipathic alpha-helical domain from HIV gp41
[10]. This heterologous complementation demonstrates
the presence of amphipathic alpha-helical structures on
the HSV virion surface (as well as all herpesviruses includ-
ing CMV) with comparable functionality to similar struc-
tures in gp41 of HIV-1. Thus, gB and gH may contain
domains amenable to AP interaction whose inhibition
would be consistent with the entry and attachment inhi-
bition observed with these compounds in HSV-1/2 [6]
and with the antiviral activity consistent with entry inhibi-
tion in CMV. While the target of AP interaction in CMV
has not yet been defined, these observations strongly sug-
gest that interactions of APs with gB and or gH in CMV
may be responsible for the inhibition of CMV viral entry.
In murine models, treatment with CpG ODN reduces the
severity and time course of infection and facilitates the
clearance of viruses such as HSV type 2, Friend retrovirus
and influenza [42-44]. Since several studies have shown
the involvement of Toll-like receptors (and specifically
TLR-9) in the progression of CMV infection [45-48], it is
also possible that CpG mediated immunomodulation
might be another mechanism whereby REP 9 could indi-
recty affect viral replication via cytokine stimulation.
However, the activity of REP 9C (which is devoid of CpG
motifs) in this model system argues that the efficacy of
APs in vivo against CMV infection is mainly derived from
the direct antiviral activity of APs. Interestingly, REP 9C
still maintained residual IL-1β and TNF-α induction in
human PBMCs which have pro-viral [49] or antiviral
activity [50], respectively. While this cytokine induction in
human PBMCs in vitro cannot be directly translated into
potential immunomodulatory activity in murine models
in vivo, it is possible that some form of cytokine induction
may influence the overall antiviral activity of REP 9C in
vivo. Splenomegaly was also observed in these studies but
only with REP 9 and only in MCMV-infected animals
treated with REP 9. It is possible that splenomegaly
induced by REP 9 only during MCMV infection could be
due to cytokine induction. Further studies are needed to
address the underlying mechanism of REP 9-induced
splenomegaly.
Phosphorothioate oligonucelotides are known to have
limited stability to acid hydrolysis below pH 5, and even
when delivered interduodenally to bypass gastric acidity,
require intestinal absorption enhancers to achieve sys-
temic exposure [37]. REP 9C is resistant to acid hydrolysis
for 24 h at pH1 [17]. This acid resistance is due to the i-
plex DNA structure adopted by polypyrimidine sequences
[51]. This i-plex structure may also be a factor in the
enhanced nuclease stability of REP 9C. The acid stability
of REP 9C is predicted to overcome the need for protec-
tion from gastric degradation, one of the hurdles in the
development of an oral formulation with phosphorothio-
ate oligonucleotides. This is supported by the antiviral
activity of an oral formulation of REP 9C with either of
two different intestinal absorption enhancers in the
absence of any protection from acidic degradation in the
digestive tract. The activity of 400 mg/kg of orally admin-
istered REP 9C was comparable to that of 20 mg/kg of REP
9C administered parenterally, demonstrating that REP 9C
can maintain its bioactivity after passing though the diges-Virology Journal 2009, 6:214 http://www.virologyj.com/content/6/1/214
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tive tract. Although the calculated minimum oral bioavail-
ability of REP 9C with these formulations was only 5%, it
should be stressed that these experiments were performed
with crude formulations which were not optimized for
efficient intestinal absorption. Moreover, given the long
half-life of these compounds in primates and their prefer-
ential accumulation in organs where CMV infection and
replication occurs, only modest improvements in oral
bioavailability may be necessary to have an oral formula-
tion that would be viable as a prophylactic treatment for
CMV in the clinic.
The studies reported here have some limitations. We only
evaluated prophylactic administration because CMV
infections in rodent systems such as the murine model
employed in this study only display transient infections of
the spleen and liver, making the therapeutic activity of
antiviral compounds difficult to assess. While the use of
immunocompromised murine models of CMV infection
are also considered useful for evaluating the efficacy of
antiviral compounds against CMV infection [52], the effi-
cacy of REP 9 or REP 9C was not further assessed in these
models. Investigating the therapeutic activity of APs
against CMV infection is the next important step in assess-
ing the clinical potential of these compounds against
established CMV infection.
There is a need for antivirals which are effective against
multiple human herpesviruses that could be used prophy-
lactically for transplant and severely immunocompro-
mised patients. APs have been shown to have antiviral
activity in vitro against HSV-1, HSV-2, HCMV, VZV, EBV,
and HHV-6A/6B [6,17]. Importantly, REP 9 and REP 9C
appear to be well tolerated and show in vivo activity
against HSV-2 [17]. The experiments reported here extend
these observations to a systemic infection with another
herpesvirus that is an important pathogen in the immu-
nocompromised. Thus, REP 9 and REP 9C may have the
potential to be broad-spectrum anti-herpetic prophylactic
agents.
Conclusion
These studies indicate that APs exhibit potent, well toler-
ated antiviral activity against CMV infection in vivo and
represent a new class of anti-herpetic agents.
As a well-tolerated prophylactic agent, APs may be useful
to prevent CMV reinfections or reactivations in CMV-pos-
itive liver or lung transplant recipients or to prevent pri-
mary infection in CMV negative transplant recipients.
These compounds may also be useful when combined
with currently available drugs for the treatment of CMV.
Moreover, since APs are equally effective in vitro against
acyclovir and foscarnet resistant herpesviridae [17], these
compounds may be useful to treat drug-resistant CMV
strains in vivo.
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